Clinical trials: PEComa, Malignant
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft…
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02180867
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Sarcoma, Uterine Leiomyosarcoma
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas.
- Conditions
- Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma, ESS
- Trial name
- NCT07467772
- Testing
- Elacestrant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Malignant PEComa
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa
A phase 2 multi-center investigation of efficacy of nab-sirolimus (formerly known as ABI-009 or nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
- Trial name
- AMPECT (NCT02494570)
- Testing
- nab-Sirolimus
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aadi Bioscience, Inc.
Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)
A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)
This is a phase Ⅰb/Ⅱ multi-center study of safety and efficacy of Sirolimus for Injection (Albumin-bound) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
- Trial name
- NCT05625919
- Testing
- Sirolimus for Injection (Albumin Bound)
- Where
- China
- Volunteers
- 54 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
PEComa, Malignant, TSC1
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a…
- Conditions
- PEComa, Malignant, TSC1, TSC2, mTOR Pathway Abberation
- Trial name
- NCT03817515
- Testing
- ABI-009
- Sponsor
- Aadi Bioscience, Inc.
PEComas
PEComas: Natural History and Prognostic Factors
Perivascular epithelioid cell tumors are rare and characterized by the expression of myomelanocytic markers. They belong to a complex tumor family that includes angiomyolipomas, lymphangioleiomyomatosis and other soft-tissue…
- Trial name
- PEComas (NCT03916575)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Strasbourg, France
PEComa, Hemangioma
Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors
PEComa is rare tumor affecting particularly patients with Tuberous Sclerosis. Biological similarities were seen between PEComa and infantile hemangioma.
- Trial name
- PEC-Hem (NCT02334930)
- Testing
- Biopsy
- Where
- France
- Volunteers
- 13 people
- Sponsor
- University Hospital, Bordeaux
Malignant PEComa (Perivascular Epithelioid Cell Tumors)
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Study objectives: The primary objective is to determine the efficacy of BEZ235 on Objective Response Rate (best response on study) according to RECIST 1.1 criteria The secondary objectives are: To determine the progression free…
- Trial name
- NCT01690871
- Testing
- BEZ235
- Where
- Spain
- Sponsor
- Novartis Pharmaceuticals